Status:
COMPLETED
A Study To Investigate And Describe The Treatment Patterns And Effect Of Tofacitinib Indicators For Patients With Rheumatoid Arthritis
Lead Sponsor:
Pfizer
Conditions:
Arthritis, Rheumatoid
Eligibility:
All Genders
Brief Summary
This study is to investigate and describe the treatment patterns and effect of tofacitinib indicators for patients with Rheumatoid Arthritis (RA) assessing real world patient data entered in the Corro...
Eligibility Criteria
Inclusion
- Enrolled in the Corrona RA Registry and initiated tofacitinib on or after November 2012
- Initiate tofacitinib (defined as first ever use of tofacitinib) at the Corrona enrollment visit or at a Corrona follow-up visit from November 2012 onward.
- Have CDAI measured at baseline
- Have at least a 6-month follow-up visit and CDAI measured at the 6-month follow-up visit
Exclusion
- There are no exclusion criteria for this study
Key Trial Info
Start Date :
January 22 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 24 2021
Estimated Enrollment :
1712 Patients enrolled
Trial Details
Trial ID
NCT04721808
Start Date
January 22 2021
End Date
November 24 2021
Last Update
September 29 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer
New York, New York, United States, 10017